Company intelligence / Profile preview

Recce Pharmaceuticals Ltd

Sydney, New South Wales, Australiarecce.com.au ↗

Ownership: Private
Development stage: Phase 3

Overview

Recce Pharmaceuticals has completed dosing of 30 patients in a Phase II trial of RECCE 327 Topical Gel (R327G) for acute bacterial skin and skin structure infections, with preliminary data showing complete cure or significant improvement in infection symptoms. The company has received approval for an additional Phase II trial for diabetic foot infections and is preparing for registrational Phase III trials in Indonesia and Australia. Full data analysis from the Phase II trial is expected in Q1 2025.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic polymer anti-infectives
Industry: Biotech

Drug pipeline

5 assets

RECCE 327

4 more assets in the full pipeline.

Partnerships

Murdoch Children's Research Institute

Beyond the preview

Go deeper on Recce Pharmaceuticals Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recce Pharmaceuticals Ltd.